Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1

New England Journal of Medicine

Volumn 373, Issue 8, 2015, Pages 705-713

  Naggie, Susanna ^a   Cooper, Curtis ^b   Saag, Michael ^d   Workowski, Kimberly ^e   Ruane, Peter ^f   Towner, William J ^g   Marks, Kristen ^j   Luetkemeyer, Anne ^h   Baden, Rachel P ^a,m   Sax, Paul E ⁿ   Gane, Edward ^p   Santana Bagur, Jorge ^r   Stamm, Luisa M ⁱ   Yang, Jenny C ⁱ   German, Polina ⁱ   Dvory Sobol, Hadas ⁱ   Ni, Liyun ⁱ   Pang, Phillip S ⁱ   McHutchison, John G ⁱ   Stedman, Catherine A M ^q   Morales Ramirez, Javier O ^s   Bräu, Norbert ^k,l   Jayaweera, Dushyantha ^t   Colson, Amy E ^o   Tebas, Pablo ^u   Wong, David K ^c   Dieterich, Douglas ^k   Sulkowski, Mark ^v   more..

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF OTTAWA   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f Ruane Medical and Liver Health Institute   (United States)

^g KAISER PERMANENTE MEDICAL CENTER   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ GILEAD SCIENCES   (United States)

^j WEILL CORNELL MEDICAL COLLEGE   (United States)

^k MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^l VETERANS AFFAIRS MEDICAL CENTER   (United States)

^m BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

ⁿ BRIGHAM AND WOMEN S HOSPITAL   (United States)

^o Boston Community Research Initiative of New England   (United States)

^p UNIVERSITY OF AUCKLAND   (New Zealand)

^q UNIVERSITY OF OTAGO   (New Zealand)

^r UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

^s Clinical Research Puerto Rico Inc   (Puerto Rico)

^t UNIVERSITY OF MIAMI   (United States)

^u UNIVERSITY OF PENNSYLVANIA   (United States)

^v JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE; EMTRICITABINE PLUS RALTEGRAVIR PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE PLUS RILPIVIRINE PLUS TENOFOVIR DISOPROXIL; LEDIPASVIR PLUS SOFOSBUVIR; RALTEGRAVIR; RIBAVIRIN; RIBAVIRIN PLUS SOFOSBUVIR; SOFOSBUVIR; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; FLUORENE DERIVATIVE; LEDIPASVIR; URIDINE PHOSPHATE; VIRUS RNA;

ADULT; ANTIVIRAL THERAPY; ARTHRALGIA; ARTICLE; BACTERIAL PERITONITIS; CLOSTRIDIUM DIFFICILE INFECTION; COHORT ANALYSIS; CONSTIPATION; CONTROLLED STUDY; COUGHING; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DYSGEUSIA; FATIGUE; FEMALE; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 1A; HEPATITIS C VIRUS GENOTYPE 1B; HEPATITIS C VIRUS GENOTYPE 4; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; ILEUS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MULTICENTER STUDY; MUSCLE SPASM; NAUSEA; NONHUMAN; OPEN STUDY; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; RELAPSE; RESPIRATORY TRACT INFECTION; SEPSIS; SINUSITIS; SUBSTANCE ABUSE; SUSTAINED VIROLOGIC RESPONSE; TREATMENT FAILURE; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; UREMIA; VOMITING; ANALOGS AND DERIVATIVES; ANTIVIRAL RESISTANCE; BLOOD; CLINICAL TRIAL; COMPLICATION; DRUG COMBINATION; DRUG EFFECTS; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; ISOLATION AND PURIFICATION; MIDDLE AGED; PHASE 3 CLINICAL TRIAL; VIRUS LOAD;

ANTI-RETROVIRAL AGENTS; ANTIVIRAL AGENTS; BENZIMIDAZOLES; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; FLUORENES; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; RNA, VIRAL; URIDINE MONOPHOSPHATE; VIRAL LOAD;

EID: 84939824828     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1501315     Document Type: Article

References (27)

1. Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 2006; 44: Suppl: S6-S9.
2. Br.u N, Fox RK, Xiao P, et al. Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: A U.S.- Canadian multicenter study. J Hepatol 2007; 47: 527-37.
3. Giordano TP, Kramer JR, Souchek J, Richardson P, El-Serag HB. Cirrhosis and hepatocellular carcinoma in HIV-infected veterans with and without the hepatitis C virus: A cohort study, 1992-2001. Arch Intern Med 2004; 164: 2349-54.
4. Kramer JR, Giordano TP, Souchek J, Richardson P, Hwang LY, El-Serag HB. The effect of HIV coinfection on the risk of cirrhosis and hepatocellular carcinoma in U.S. veterans with hepatitis C. Am J Gastroenterol 2005; 100: 56-63.
5. Lo Re V III, Kallan MJ, Tate JP, et al. Hepatic decompensation in antiretroviral- treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: A cohort study. Ann Intern Med 2014; 160: 369-79.
6. Kirk GD, Mehta SH, Astemborski J, et al. HIV, age, and the severity of hepatitis C virus-related liver disease: A cohort study. Ann Intern Med 2013; 158: 658-66.
7. Thein HH, Yi Q, Dore GJ, Krahn MD. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: A meta-analysis. AIDS 2008; 22: 1979-91.
8. Smith CJ, Ryom L, Weber R, et al. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D: A: D): A multicohort collaboration. Lancet 2014; 384: 241-8.
9. Limketkai BN, Mehta SH, Sutcliffe CG, et al. Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV. JAMA 2012; 308: 370-8.
10. Berenguer J, Alvarez-Pellicer J, Martín PM, et al. Sustained virological response to interferon plus ribavirin reduces liverrelated complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 2009; 50: 407-13.
11. Chung RT, Andersen J, Volberding P, et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 351: 451-9.
12. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351: 438-50.
13. Alvarez D, Dieterich DT, Brau N, Moorehead L, Ball L, Sulkowski MS. Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons. J Viral Hepat 2006; 13: 683-9.
14. Sulkowski MS, Sherman KE, Dieterich DT, et al. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: A randomized trial. Ann Intern Med 2013; 159: 86-96.
15. Sulkowski M, Pol S, Mallolas J, et al. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: A randomised, doubleblind, controlled phase 2 trial. Lancet Infect Dis 2013; 13: 597-605.
16. Sulkowski MS, Naggie S, Lalezari J, et al. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. JAMA 2014; 312: 353-61.
17. Rockstroh JK, Puoti M, Rodriguez- Torres M, et al. Sofosbuvir and ribavirin therapy for the treatment of HIV/HCV coinfected patients with HCV GT 1-4 infection: The PHOTON-1 and -2 trials. Presented at the 65th Annual Meeting of the American Association for the Study of Liver Diseases, Boston, November 7-11, 2014. abstract.
18. Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive pa- tients: The COSMOS randomised study. Lancet 2014; 384: 1756-65.
19. Harvoni (ledipasvir-sofosbuvir) tablets: U.S. prescribing information. Foster City, CA: Gilead Sciences, March 2015 (http: //www .gilead .com/ media/ Files/ pdfs/ medicines/ liver-disease/ harvoni/ harvoni-pi .pdf).
20. Osinusi A, Townsend K, Kohli A, et al. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. JAMA 2015; 313: 1232-9.
21. Code of Federal Regulations. Phases of an investigation. 21 CFR 312.21. 2013.
22. German P, Pang PS, Fang L, Chung D, Mathias A. Drug-drug interaction profile of the fixed-dose combination tablet ledipasvir/ sofosbuvir. Presented at the 65th Annual Meeting of the American Association for the Study of Liver Diseases, Boston, November 7-11, 2014. abstract.
23. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370: 1889-98.
24. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370: 1483-93.
25. Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014; 370: 1879-88.
26. Haas DW, Ribaudo HJ, Kim RB, et al. Pharmacogenetics of efavirenz and central nervous system side effects: An Adult AIDS Clinical Trials Group study. AIDS 2004; 18: 2391-400.
27. German P, Garrison K, Pang PS, et al. Drug interactions between the anti-HCV regimen ledipasvir/sofosbuvir and ritonavir boosted protease inhibitors plus emtricitabine/ tenofovir DF. Presented at the annual Conference on Retroviruses and Opportunistic Infections, Seattle, February 23-26, 2015.